Financhill
Buy
54

IMTX Quote, Financials, Valuation and Earnings

Last price:
$5.75
Seasonality move :
7.36%
Day range:
$5.65 - $6.16
52-week range:
$3.30 - $13.77
Dividend yield:
0%
P/E ratio:
42.21x
P/S ratio:
4.19x
P/B ratio:
1.20x
Volume:
552.5K
Avg. volume:
609.9K
1-year change:
-53.7%
Market cap:
$698.9M
Revenue:
$168.7M
EPS (TTM):
-$0.19

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IMTX
Immatics NV
$15.4M -$0.33 -35.38% -96.4% $14.33
ATAI
ATAI Life Sciences NV
-- -$0.18 -100% -69.44% $8.00
BNTX
BioNTech SE
$183.4M -$2.66 17.63% -35.99% $133.41
CVAC
CureVac NV
$3.7M -$0.21 -69.02% -51.1% $6.29
EVO
Evotec SE
$243.3M -$0.01 16.7% -75.1% $6.3925
IFRX
InflaRx NV
$36.3K -$0.20 256.48% -10.49% $3.62
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IMTX
Immatics NV
$5.75 $14.33 $698.9M 42.21x $0.00 0% 4.19x
ATAI
ATAI Life Sciences NV
$2.47 $8.00 $494.8M -- $0.00 0% 218.10x
BNTX
BioNTech SE
$111.15 $133.41 $26.7B 191.55x $0.00 0% 9.01x
CVAC
CureVac NV
$4.44 $6.29 $999.7M 4.92x $0.00 0% 1.74x
EVO
Evotec SE
$4.1000 $6.3925 $1.5B -- $0.00 0% 1.72x
IFRX
InflaRx NV
$0.85 $3.62 $57.6M -- $0.00 0% 280.79x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IMTX
Immatics NV
-- 0.516 -- 9.87x
ATAI
ATAI Life Sciences NV
13.53% 5.785 8.75% 3.50x
BNTX
BioNTech SE
1.53% 1.010 1.45% 9.86x
CVAC
CureVac NV
-- 0.986 -- 7.39x
EVO
Evotec SE
6.26% 1.519 5.55% 1.77x
IFRX
InflaRx NV
-- 1.638 -- 3.85x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IMTX
Immatics NV
-- -$37.2M -4.67% -4.67% -218.49% -$39.3M
ATAI
ATAI Life Sciences NV
-- -$20.3M -81.4% -92.32% -1634.02% -$18.1M
BNTX
BioNTech SE
$104.2M -$562M -3.86% -3.91% -225.11% -$1.5B
CVAC
CureVac NV
$18.9K -$57.6M 32.68% 32.68% -5747.14% -$44.1M
EVO
Evotec SE
$28.6M -$20.9M -14.69% -20.84% -13.72% -$56.4M
IFRX
InflaRx NV
-$9.8K -$13.7M -56.78% -56.78% 1207051.66% -$14.8M

Immatics NV vs. Competitors

  • Which has Higher Returns IMTX or ATAI?

    ATAI Life Sciences NV has a net margin of -214.48% compared to Immatics NV's net margin of -1699.74%. Immatics NV's return on equity of -4.67% beat ATAI Life Sciences NV's return on equity of -92.32%.

    Company Gross Margin Earnings Per Share Invested Capital
    IMTX
    Immatics NV
    -- -$0.35 $580.8M
    ATAI
    ATAI Life Sciences NV
    -- -$0.15 $176.1M
  • What do Analysts Say About IMTX or ATAI?

    Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand ATAI Life Sciences NV has an analysts' consensus of $8.00 which suggests that it could grow by 223.89%. Given that ATAI Life Sciences NV has higher upside potential than Immatics NV, analysts believe ATAI Life Sciences NV is more attractive than Immatics NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMTX
    Immatics NV
    7 0 0
    ATAI
    ATAI Life Sciences NV
    5 0 0
  • Is IMTX or ATAI More Risky?

    Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison ATAI Life Sciences NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IMTX or ATAI?

    Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ATAI Life Sciences NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. ATAI Life Sciences NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMTX or ATAI?

    Immatics NV quarterly revenues are $19.6M, which are larger than ATAI Life Sciences NV quarterly revenues of $1.6M. Immatics NV's net income of -$41.9M is lower than ATAI Life Sciences NV's net income of -$26.4M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while ATAI Life Sciences NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 218.10x for ATAI Life Sciences NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMTX
    Immatics NV
    4.19x 42.21x $19.6M -$41.9M
    ATAI
    ATAI Life Sciences NV
    218.10x -- $1.6M -$26.4M
  • Which has Higher Returns IMTX or BNTX?

    BioNTech SE has a net margin of -214.48% compared to Immatics NV's net margin of -227.46%. Immatics NV's return on equity of -4.67% beat BioNTech SE's return on equity of -3.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    IMTX
    Immatics NV
    -- -$0.35 $580.8M
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
  • What do Analysts Say About IMTX or BNTX?

    Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand BioNTech SE has an analysts' consensus of $133.41 which suggests that it could grow by 20.04%. Given that Immatics NV has higher upside potential than BioNTech SE, analysts believe Immatics NV is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMTX
    Immatics NV
    7 0 0
    BNTX
    BioNTech SE
    14 5 0
  • Is IMTX or BNTX More Risky?

    Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.

  • Which is a Better Dividend Stock IMTX or BNTX?

    Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMTX or BNTX?

    Immatics NV quarterly revenues are $19.6M, which are smaller than BioNTech SE quarterly revenues of $192.3M. Immatics NV's net income of -$41.9M is higher than BioNTech SE's net income of -$437.5M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 9.01x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMTX
    Immatics NV
    4.19x 42.21x $19.6M -$41.9M
    BNTX
    BioNTech SE
    9.01x 191.55x $192.3M -$437.5M
  • Which has Higher Returns IMTX or CVAC?

    CureVac NV has a net margin of -214.48% compared to Immatics NV's net margin of -5832.47%. Immatics NV's return on equity of -4.67% beat CureVac NV's return on equity of 32.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    IMTX
    Immatics NV
    -- -$0.35 $580.8M
    CVAC
    CureVac NV
    2.02% -$0.24 $699.9M
  • What do Analysts Say About IMTX or CVAC?

    Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand CureVac NV has an analysts' consensus of $6.29 which suggests that it could grow by 41.7%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMTX
    Immatics NV
    7 0 0
    CVAC
    CureVac NV
    2 2 0
  • Is IMTX or CVAC More Risky?

    Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IMTX or CVAC?

    Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMTX or CVAC?

    Immatics NV quarterly revenues are $19.6M, which are larger than CureVac NV quarterly revenues of $939.6K. Immatics NV's net income of -$41.9M is higher than CureVac NV's net income of -$54.8M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while CureVac NV's PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 1.74x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMTX
    Immatics NV
    4.19x 42.21x $19.6M -$41.9M
    CVAC
    CureVac NV
    1.74x 4.92x $939.6K -$54.8M
  • Which has Higher Returns IMTX or EVO?

    Evotec SE has a net margin of -214.48% compared to Immatics NV's net margin of -15.79%. Immatics NV's return on equity of -4.67% beat Evotec SE's return on equity of -20.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    IMTX
    Immatics NV
    -- -$0.35 $580.8M
    EVO
    Evotec SE
    13.62% -$0.09 $1.1B
  • What do Analysts Say About IMTX or EVO?

    Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand Evotec SE has an analysts' consensus of $6.3925 which suggests that it could grow by 59.88%. Given that Immatics NV has higher upside potential than Evotec SE, analysts believe Immatics NV is more attractive than Evotec SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMTX
    Immatics NV
    7 0 0
    EVO
    Evotec SE
    1 0 0
  • Is IMTX or EVO More Risky?

    Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison Evotec SE has a beta of 1.656, suggesting its more volatile than the S&P 500 by 65.647%.

  • Which is a Better Dividend Stock IMTX or EVO?

    Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMTX or EVO?

    Immatics NV quarterly revenues are $19.6M, which are smaller than Evotec SE quarterly revenues of $210.4M. Immatics NV's net income of -$41.9M is lower than Evotec SE's net income of -$33.2M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 1.72x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMTX
    Immatics NV
    4.19x 42.21x $19.6M -$41.9M
    EVO
    Evotec SE
    1.72x -- $210.4M -$33.2M
  • Which has Higher Returns IMTX or IFRX?

    InflaRx NV has a net margin of -214.48% compared to Immatics NV's net margin of -14092.9%. Immatics NV's return on equity of -4.67% beat InflaRx NV's return on equity of -56.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    IMTX
    Immatics NV
    -- -$0.35 $580.8M
    IFRX
    InflaRx NV
    -5376.61% -$0.14 $63.9M
  • What do Analysts Say About IMTX or IFRX?

    Immatics NV has a consensus price target of $14.33, signalling upside risk potential of 149.28%. On the other hand InflaRx NV has an analysts' consensus of $3.62 which suggests that it could grow by 325.65%. Given that InflaRx NV has higher upside potential than Immatics NV, analysts believe InflaRx NV is more attractive than Immatics NV.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMTX
    Immatics NV
    7 0 0
    IFRX
    InflaRx NV
    5 1 0
  • Is IMTX or IFRX More Risky?

    Immatics NV has a beta of 0.827, which suggesting that the stock is 17.335% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.287, suggesting its more volatile than the S&P 500 by 28.694%.

  • Which is a Better Dividend Stock IMTX or IFRX?

    Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMTX or IFRX?

    Immatics NV quarterly revenues are $19.6M, which are larger than InflaRx NV quarterly revenues of -$450. Immatics NV's net income of -$41.9M is lower than InflaRx NV's net income of -$8.7M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 4.19x versus 280.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMTX
    Immatics NV
    4.19x 42.21x $19.6M -$41.9M
    IFRX
    InflaRx NV
    280.79x -- -$450 -$8.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is It Time to Sell MercadoLibre?
Is It Time to Sell MercadoLibre?

MercadoLibre (NASDAQ:MELI) has earned a reputation for being not dissimilar…

Is Tesla Stock High Risk or High Reward?
Is Tesla Stock High Risk or High Reward?

EV-making supergiant Tesla, Inc. (NASDAQ:TSLA) is going through a difficult…

Why Did Chase Coleman Buy TSM?
Why Did Chase Coleman Buy TSM?

Billionaire Chase Coleman of Tiger Global Management has built a…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
76
SBET alert for Jun 5

SharpLink Gaming [SBET] is down 27.96% over the past day.

Buy
80
GWRE alert for Jun 5

Guidewire Software [GWRE] is up 0.78% over the past day.

Buy
70
ZLAB alert for Jun 5

Zai Lab [ZLAB] is up 1.27% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock